Barclays analyst Luke Sergott lowered the firm’s price target on Repligen (RGEN) to $145 from $175 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science and diagnostic tools group as part of a Q1 preview. Barclays likes the setup for the sector but says it is “not without risk.” Sentiment is at all-time lows and Barclays still believes in the “last-cut thesis (for the most part),” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen price target lowered to $140 from $170 at Evercore ISI
- Repligen: Strong Execution, Innovation, and Cross‑Selling Momentum Support Sustained Growth and Reaffirmed Buy Rating
- Repligen price target raised to $208 from $180 at H.C. Wainwright
- Repligen price target lowered to $195 from $200 at UBS
- Repligen price target lowered to $170 from $180 at Evercore ISI